YOUR BUSINESS AUTHORITY
Springfield, MO
Pfizer has terminated a co-development agreement with Sangamo Therapeutics, the latter company announced on Monday.
The companies had planned to co-develop a hemophilia A gene therapy.
Sangamo is exploring options for the therapy, including the addition of a new partner.
Read more from Reuters.
Project work in Springfield corridor will continue into 2031.